Inventor

Juswinder Singh

Inventor

Ashland, MA, US

Overview

1999–2021

Patent span

Human necessities

Primary field (CPC A)

Patents· 65 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

A61Pprimary

A61PSpecific therapeutic activity of chemical compounds or medicinal preparations25%

A61KPreparations for medical, dental or toiletry purposes24%

C07DHeterocyclic compounds24%

C12NMicroorganisms or enzymes7%

C12YEnzymes6%

C07KPeptides6%

C07FAcyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium2%

C07BGeneral methods of organic chemistry2%

Y02PClimate change mitigation technologies in the production or processing of goods2%

C07CAcyclic or carbocyclic compounds1%

PatentTitleYear

11,057,306Traffic overload protection of virtual network functions2021 10,828,300Substituted 2,4-diaminopyrimidines as kinase inhibitors2020 10,774,052Heteroaryl compounds and uses thereof2020 10,662,195Protein kinase conjugates and inhibitors2020 10,618,902Substituted pyrido[2,3-d]pyrimidines as inhibitors of protein kinases2020 10,596,1722,4-disubstituted pyrimidines useful as kinase inhibitors2020 10,577,380MK2 inhibitors and uses thereof2020 10,434,101Heterocyclic compounds and uses thereof2019 10,253,040MK2 inhibitors and uses thereof2019 10,189,794Heteroaryl compounds and uses thereof2019 10,138,256MK2 inhibitors and uses thereof2018 10,081,606Heteroaryl compounds and uses thereof2018 10,065,966Substituted pyrido[2,3-d]pyrimidines as inhibitors of protein kinases2018 10,010,5482,4-disubstituted pyrimidines useful as kinase inhibitors2018 9,987,276Substituted 2,4-diaminopyrimidines as kinase inhibitors2018 9,980,964ERK inhibitors and uses thereof2018 9,867,824'Heterocyclic compounds and uses thereof'2018 9,796,700'ERK inhibitors and uses thereof'2017 9,790,235'MK2 inhibitors and uses thereof'2017 9,765,038'Heteroaryl compounds and uses thereof'2017 9,695,132'Heteroaryl compounds and uses thereof'2017 9,694,086'HCV protease inhibitors and uses thereof'2017 9,676,785'HCV protease inhibitors and uses thereof'2017 9,663,524'Substituted pyrido[2,3-d]pyrimidines as protein kinase inhibitors'2017 9,561,228'ERK inhibitors and uses thereof'2017 9,556,426'Protein kinase conjugates and inhibitors'2017 9,504,686'ERK inhibitors and uses thereof'2016 9,458,175'MK2 inhibitors and uses thereof'2016 9,422,333'HCV protease inhibitors and uses thereof'2016 9,409,921'2,4-disubstituted pyrimidines as kinase inhibitors'2016 9,393,246'4,6-disubstituted pyrimidines as kinase inhibitors'2016 9,375,431'2,4-disubstituted pyrimidine compounds useful as kinase inhibtors'2016 9,321,786'Heteroaryl compounds and uses thereof'2016 9,296,737'Substituted 2,4-diaminopyrimidines as kinase inhibitors'2016 9,296,704'Substituted pyrimidines as protein kinase inhibitors'2016 9,238,629'Heteroaryl compounds and uses thereof'2016 9,212,181'Substituted 2,4-diaminopyrimidines as kinase inhibitors'2015 9,163,061'HCV protease inhibitors and uses thereof'2015 9,145,387'ERK inhibitors and uses thereof'2015 9,067,929'Heterocyclic compounds and uses thereof'2015 9,040,541'4,6-disubstituted pyrimidines useful as kinase inhibitors'2015 8,980,935'HCV protease inhibitors and uses thereof'2015 8,975,249'Heterocyclic compounds and uses thereof'2015 8,778,877'HCV protease inhibitors and uses thereof'2014 8,748,606'4,6-diaminopyrimidines useful as kinase inhibitors'2014 8,741,837'HCV protease inhibitors and uses thereof'2014 8,710,222'2,4-disubstituted pyrimidines useful as kinase inhibitors'2014 8,609,679'2,4-diaminopyrimidines useful as kinase inhibitors'2013 8,586,600'Heterocyclic compounds and uses thereof'2013 8,524,760'HCV protease inhibitors and uses thereof'2013 8,450,335'2,4-disubstituted pyrimidines useful as kinase inhibitors'2013 8,445,498'4,6-disubstituted pyrimidines useful as kinase inhibitors'2013 8,338,439'2,4-disubstituted pyrimidines useful as kinase inhibitors'2012 8,329,901'4,6-disubstitued pyrimidines useful as kinase inhibitors'2012 8,309,685'HCV protease inhibitors and uses thereof'2012 8,293,705'HCV protease inhibitors and uses thereof'2012 8,242,271'Heterocyclic compounds and uses thereof'2012 8,188,137'HCV protease inhibitors and uses thereof'2012 7,989,465'4,6-disubstituted pyrimidines useful as kinase inhibitors'2011 7,982,036'4,6-disubstitued pyrimidines useful as kinase inhibitors'2011 7,691,865'Pyrazolopyridines and methods of making and using the same'2010 6,630,512'Cell adhesion inhibitors'2003 6,552,216'Molecular model for VLA-4 inhibitors'2003 6,376,538'Cell adhesion inhibitors'2002 5,922,697'Compounds, compositions and methods for inhibiting the binding of proteins containing an SH2 domain to cognate phosphorylated proteins'1999

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

1999–2003Based in Malden, MA, US· patent location history

2003–2020Based in Ashland, MA, US· patent location history

2012–2020Patents assigned to CELGENE AVILOMICS RES INC (32)· patent assignee history

2012–2017Patents assigned to SINGH JUSWINDER (16)· patent assignee history

2012–2016Patents assigned to PETTER RUSSELL C (13)· patent assignee history

2012–2017Patents assigned to NIU DEQIANG (12)· patent assignee history

2015–2020Based in Southborough, MA, US· patent location history

2017–2020Patents assigned to CELGENE CAR LLC (23)· patent assignee history

2021Based in Shannon, IE· patent location history

Inventor activity

Assignee and location history derived from the patent record.

Assignees

Assignee	Patents	Span
CELGENE AVILOMICS RES INC	32	2012–2020
CELGENE CAR LLC	23	2017–2020
SINGH JUSWINDERself	16	2012–2017
PETTER RUSSELL C	13	2012–2016
NIU DEQIANG	12	2012–2017

Locations

Location	Patents	Span
Ashland, Massachusetts, US	38	2003–2020
Southborough, Massachusetts, US	23	2015–2020
Malden, Massachusetts, US	3	1999–2003
Shannon, IE	1	2021